Having established correlations between ITGB6, GDI2, RAB5A, and RAB7A expression and considering that elevated ITGB6 expression has been identified as an unfavorable prognostic factor among patients with HER2+ breast cancer (17), we explored whether coexpression of GDI2, RAB5A, or RAB7A with elevated ITGB6 could further predict prognosis. Here, ERBB2 is linked to breast cancer.